[ad_1]
Prof. Dr. Uğur Şahin and Dr. The CEO of Pfizer, Albert Bourla, who is the most authorized name of the company, announced when the first application of the vaccine developed by the BioNTech company founded by Özlem Türeci with the American pharmaceutical company could be made Pfizer.
It is estimated that the vaccination will begin on December 13 at the earliest, after the US pharmaceutical giant Pfizer and Biontech asked the US Food and Drug Administration (FDA) for approval of the vaccine developed against Covid-19 and they announced that it is 95 percent effective. .
The president of “Operation Warp Speed”, Moncef Slaoui, initiated by the Trump administration for the studies of the Covid-19 vaccine, told CNN television: “We plan to send the vaccine to vaccination centers within 24 hours after to approval “. said.
Slaoui said they expected the approval to end on December 11-12.
Vaccination procedures are expected to start with healthcare professionals first.
CEO ALBERT BOURLA ANNOUNCED THE STORY IN ONE DAY
Albert Bourla, CEO of US pharmaceutical giant Pfizer, said in the video posted Friday: “Today is a historic day, today is a historic day for science and for all of us.”
“It has been 248 days from the day we announced our plans to cooperate with BioNTech, until the request we made today to the US Food and Drug Administration,” Bourla said in his message.
Albert Bourla continued: “From concept to license applications, we have worked at an extraordinary pace in our clinical development program, always maintaining our focus on safety.”
Pfizer was the first US company to apply for a coronavirus vaccine license. According to the statement made today by Pfizer and BioNTech; The candidate vaccine known as ‘BNT 162b2’ could potentially be used in high-risk population groups in the US in mid-December.
MINISTER KOCA: 1 MILLION DOSE WILL COME IN THE FIRST STAGE
Health Minister Fahrettin husband, will be granted a license in December, said the first chorus vaccine virus and Turkey announced that it will supply 1 million doses.
Fahrettin Koca, Prof. Dr. Uğur Şahin and Dr. Özlem Türeci added that the vaccine developed by the BioNTech company, managed by the couple, could increase the amount of supply to 25 million doses in 2021.
The application to the US Drug Administration is based on the results of phase 3 clinical trials of the vaccine. Vaccine trials began in the US on July 27, and more than 43,000 people were tested in the process.
SOURCE: ANADOLU AGENCY
